When Wegovy crosses borders, who actually gets closer to treatment? New to this story? Here’s where it stands. South Korea has been weighing managed insurance coverage for obesity drugs while regulators tackle misuse. Hanmi’s Eppe entered select clinics without insurance coverage, competing with Wegovy and Mounjaro on supply prices. Meanwhile, the Korea Customs Service recorded 5,030 interceptions of illegal obesity-drug imports in the first eight months of 2026, underscoring demand beyond the domestic prescription market. On GLP-1 Daily: what Korea’s import shift and Aspen’s approvals could change—and why that Saudi-made label needs a closer look. First, Korea’s mixed signals.
From Kim Dong-young at Aju Press:
From Thursday, travelers may carry in prescribed obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, the Ministry of Food and Drug Safety (MFDS) said. The medicines must be approved by the relevant country's regulator and legally prescribed and purchased. The general allowance is six containers, with larger quantities permitted within a three-month supply — equivalent to 12 or 13 single-dose weekly Mounjaro pens. Online direct purchases remain prohibited, while narcotics and psychotropic medicines are excluded from the relaxation.
South Korea’s obesity-drug crackdown now has a traveler exception: legally prescribed medicines bought abroad can come home with you; online orders remain banned. Aju Press reports lower prices in places like Japan. That’s a useful opening—provided you can afford the trip. And there are guardrails: the medicine needs approval in the country where it’s bought, plus a legal prescription and purchase. Korea Customs recorded 5,030 illegal-import interceptions in the first eight months of this year—4.2 times the entire 2025 total. A lawful route makes sense against that pressure; customs monitoring still needs to mean something. Yes, keep those safeguards. But Aju’s example is a Busan travel-agency operator who picks up medication on trips to Japan. Someone who can’t travel still needs an affordable route to treatment. This exception gives those two patients very different options.
From Bizcommunity:
South African pharmaceutical company Aspen Pharmacare said it had received regulatory approval in Brazil and South Africa for its generic injectable semaglutide, paving the way for launches in two key emerging markets.
Aspen says its generic injectable semaglutide has regulatory approval in Brazil and South Africa. Two markets where another supplier could matter for access—but I want to see the patient price before celebrating the savings. And keep the geography attached to that headline. Bizcommunity reports Aspen's approval announcement for Brazil and South Africa; the company also expects commercialisation in Canada in the coming months. Those are different claims, and none means it's on a pharmacy shelf today. Aspen also has a foot in the competition's camp: it distributes Lilly's Mounjaro in sub-Saharan Africa. By Aspen's own figures, Mounjaro holds more than half of South Africa's nearly three-billion-rand GLP-1 market—so Aspen can benefit on both sides of this contest. Which makes the launch price especially interesting. Aspen is betting on generic semaglutide for growth; patients need that competition to translate into a prescription they can actually afford to refill.
Saudiweek writes:
Avalon Pharma has put a large number on its licence to sell a generic version of tirzepatide, the drug Eli Lilly markets as Mounjaro and Zepbound. It has not put a date on it. The details point to a long wait, and a longer one for tirzepatide made in Saudi Arabia.
Avalon’s tirzepatide licence comes with an expected revenue haul of at least 800 million Saudi riyals over five years after launch. That last bit—after launch—is where patients should keep their eyes. Saudiweek reports there’s no launch date. And the deal with India’s OneSource requires relevant patents to expire in both the market selling it and the country making it. Signing a licence doesn’t clear either hurdle, or mean Saudi-made tirzepatide is ready. That 800 million also spans Saudi Arabia and other Middle East and North Africa markets. You can’t turn Avalon’s revenue expectation into a promise about what a Saudi patient will pay—or when they’ll get a cheaper option. And don’t circle 2036 on a Saudi calendar. The Medicines Patent Pool’s estimate for the main patent covers certain low- and middle-income countries; Saudiweek says Saudi Arabia’s dates remain unconfirmed. A precise revenue number can sit beside a very uncertain wait.
If GLP-1 Daily helps you stay informed, please subscribe and leave us a review wherever you’re listening. Your review helps other people find the show, and we’re grateful to have you with us.
We’re watching Aspen’s expected start of commercializing generic injectable semaglutide in Canada, Brazil, and South Africa in the coming months. Links to every story are in the show notes, so take a look at the ones you’d like to explore further. That’s GLP-1 Daily for today. This is a Lantern Podcast.